The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 351:98-100 July 1, 2004 Number 1
NextNext

Intensive Therapy for Aggressive Lymphoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lister, T. A.
-Related Article
by Milpied, N.
To the Editor: Milpied et al. (March 25 issue)1 provide further information about the benefits of high-dose chemotherapy plus autologous stem-cell support in the initial treatment of aggressive lymphoma. However, almost 50 percent of the patients were at low or low intermediate risk, according to the International Prognostic Index, and it seems that such patients may not benefit from intensive therapy.2

New strategies — for example, high-dose chemotherapy and autologous stem-cell support given initially or at the time of a first relapse, regimens with either higher doses or shorter intervals between cycles,3 and strategies in which monoclonal antibodies are added . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.